Catheter Precision Inc. announced on February 10, 2025, its engagement with PCG Advisory, an investor relations, strategic communications, and digital strategies firm. This partnership aims to enhance investor outreach and communication efforts.
The company seeks to strengthen its engagement with institutional and retail investors and effectively communicate its strategic vision. This initiative is intended to increase market awareness of its LockeT and VIVO technologies.
David Jenkins, CEO of Catheter Precision, stated that a strong investor relations strategy supported by PCG Advisory will help share the company's story as it expands operations. The electrophysiology market is projected to reach $15.1 billion by 2028, indicating a significant growth opportunity for the company's products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.